{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:50:13Z","timestamp":1791039013144,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.neulet.2006.08.036","type":"journal-article","created":{"date-parts":[[2006,9,8]],"date-time":"2006-09-08T19:49:03Z","timestamp":1157744943000},"page":"219-223","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease"],"prefix":"10.1016","volume":"407","author":[{"given":"Jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieshan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Bezprozvanny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2006.08.036_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mds.10629","article-title":"Hyperhomocysteinaemia in treated patients with Huntington's disease","volume":"19","author":"Andrich","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2006.08.036_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease","author":"Beister","year":"2004","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.neulet.2006.08.036_bib3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbrc.2004.08.035","article-title":"Deranged neuronal calcium signaling and Huntington disease","volume":"322","author":"Bezprozvanny","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neulet.2006.08.036_bib4","first-page":"s324","article-title":"Safety and tolerability of lamotrigine in Huntington's disease","volume":"17","author":"Higgins","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2006.08.036_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","article-title":"Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease","volume":"21","author":"Hockly","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neulet.2006.08.036_bib6","unstructured":"Huntington's Outreach Project for Education at Stanford, Glutamate Toxicity, Disease Mechanism V, Stanford University, 2006."},{"key":"10.1016\/j.neulet.2006.08.036_bib7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","author":"Huntington's Study Group","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2006.08.036_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2006.08.036_bib9","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1523\/JNEUROSCI.20-18-06920.2000","article-title":"Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity","volume":"20","author":"Kruman","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2006.08.036_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neulet.2006.08.036_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-328X(00)00276-X","article-title":"Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons","volume":"86","author":"Mao","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neulet.2006.08.036_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neulet.2006.08.036_bib13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2006.08.036_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neulet.2006.08.036_bib15","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1073\/pnas.0409402102","article-title":"Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease","volume":"102","author":"Tang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neulet.2006.08.036_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0896-6273(03)00366-0","article-title":"Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1","volume":"39","author":"Tang","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2006.08.036_bib17","doi-asserted-by":"crossref","unstructured":"The Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell 72 (1993) 971\u201383.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"10.1016\/j.neulet.2006.08.036_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neulet.2006.08.036_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neulet.2006.08.036_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.mcn.2003.11.014","article-title":"Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease","volume":"25","author":"Zeron","year":"2004","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neulet.2006.08.036_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2006.08.036_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00210-004-0959-9","article-title":"Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease","volume":"370","author":"Zucker","year":"2004","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394006008433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394006008433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T02:48:21Z","timestamp":1555814901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394006008433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0304394006008433"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2006.08.036","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}